PGGM Investments Buys 60,384 Shares of Illumina, Inc. (NASDAQ:ILMN)

PGGM Investments raised its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 39.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 211,834 shares of the life sciences company’s stock after purchasing an additional 60,384 shares during the quarter. PGGM Investments owned 0.13% of Illumina worth $29,496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of ILMN. Global Retirement Partners LLC lifted its position in Illumina by 36.5% during the third quarter. Global Retirement Partners LLC now owns 714 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 191 shares during the last quarter. Czech National Bank lifted its position in Illumina by 47.8% during the third quarter. Czech National Bank now owns 27,668 shares of the life sciences company’s stock valued at $3,798,000 after purchasing an additional 8,953 shares during the last quarter. Slow Capital Inc. lifted its position in Illumina by 6.6% during the third quarter. Slow Capital Inc. now owns 35,155 shares of the life sciences company’s stock valued at $4,826,000 after purchasing an additional 2,169 shares during the last quarter. Linden Thomas Advisory Services LLC lifted its holdings in shares of Illumina by 121.8% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 9,077 shares of the life sciences company’s stock worth $1,246,000 after acquiring an additional 4,984 shares during the last quarter. Finally, Chevy Chase Trust Holdings LLC lifted its holdings in shares of Illumina by 2.8% in the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 533,414 shares of the life sciences company’s stock worth $73,227,000 after acquiring an additional 14,342 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the subject of a number of recent research reports. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, January 16th. StockNews.com upgraded shares of Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price objective for the company. in a report on Thursday, January 4th. Barclays boosted their price objective on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Finally, OTR Global restated a “mixed” rating on shares of Illumina in a report on Wednesday, March 20th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of “Hold” and a consensus target price of $167.70.

Illumina Trading Up 1.0 %

Illumina stock traded up $1.23 during mid-day trading on Friday, reaching $122.28. 829,331 shares of the company traded hands, compared to its average volume of 1,470,247. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The firm’s 50 day moving average price is $131.51 and its 200 day moving average price is $127.39. The firm has a market capitalization of $19.47 billion, a price-to-earnings ratio of -16.66 and a beta of 1.19. Illumina, Inc. has a 52-week low of $89.00 and a 52-week high of $213.91.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. Illumina had a negative net margin of 25.78% and a positive return on equity of 2.20%. The company’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 EPS. On average, analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In related news, CEO Jacob Thaysen acquired 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The shares were acquired at an average cost of $135.29 per share, with a total value of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 0.17% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.